Secukinumab In Psoriasis Research Articles

Real-world retention rates and effectiveness of secukinumab in psoriasis: Results from a multicenter cohort study (RAILWAY).

Psoriasis is a chronic, immune-mediated inflammatory skin disease with a high negative impact on patient's quality of life. Secukinumab, the first interleukin 17A inhibitor, has been used for the systemic treatment of psoriasis, but its long-term, real-world retention rates in Japan have not been fully investigated. In this multicenter, noninterventional, retrospective chart review study, the retention rate of secukinumab and its effectiveness among patients with psoriasis in Japan was evaluated up to 5 years. Data of patients who received secukinumab after December 26, 2014, were collected from medical charts obtained from seven sites, all certified for biologics use by the Japanese Dermatological Association. Patient characteristics, secukinumab retention, factors affecting secukinumab retention, reason for drug discontinuation, and effectiveness data were collected. The primary end point was secukinumab retention rate at week 52. A total of 123 patients were included in the analysis. Of these, 27 patients discontinued secukinumab by week 52, yielding a 78.0% (95% confidence interval, 69.6-84.4) retention rate at week 52. For patients whose Psoriasis Area and Severity Index (PASI) score was available, mean ± standard deviation PASI at baseline and at week 52 were 9.21 ± 7.37 and 1.4 ± 2.6, respectively. During the entire study period, "insufficient response" was the most common reason for discontinuation, and "history of biologics use" was a factor significantly associated with secukinumab discontinuation (hazard ratio, 1.72; p = 0.018). This study demonstrates the real-world retention rate and effectiveness of secukinumab in patients with psoriasis in Japan for up to 5 years and provides clinical insights into psoriasis treatment strategies.

Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study

Psoriasis, a common systemic inflammatory disorder, presents with gender-related differences in the quality of life (QoL) and treatment outcomes. This post hoc analysis from the Phase 3b SUPREME study explored gender-related differences in patient characteristics and efficacy of secukinumab 300 mg on Psoriasis Area and Severity Index (PASI) 75/90/100 and impact on QoL using the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis through week 24. The proportion of patients achieving PASI 75/90/100 was computed using a nonresponder imputation approach. Differences between cohorts were analyzed using a logistic regression model. The mean change from baseline in DLQI was computed using the Wilcoxon test. Among the 433 patients (males: 71.6%), females had a higher DLQI than males at baseline (13.1 vs 9.5; P<0.0001). Males had a slightly higher response for PASI 90 than females at week 16 (80.7% vs 78.1%; P=0.0779) and 24 (83.2% vs 79.7%; P=0.0319). No differences were observed between genders in PASI 100/75 responses at week 24. Both genders showed an improvement in DLQI with secukinumab at week 24 (-10.9 vs -8.1, respectively, in females vs males; P=0.0004). In summary, secukinumab was effective in the treatment of psoriasis, irrespective of gender.

Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on Control.

This paper describes the innovative pediatric development strategy of secukinumab in psoriasis. Initially, this pediatric development had been planned early during the adult development program. This is common for most development programs as it is required by law in major regions worldwide. At that time, only limited experience with secukinumab's mechanism of action was available, especially in the pediatric population for which no data had been collected yet. Pediatric extrapolation frameworks were not in use. As a result, a standard pediatric program had initially been proposed requiring two relatively large placebo-controlled pivotal trials. However, as experience with the use of secukinumab grew, so did experience with-and regulatory openness to-innovative quantitative approaches, such as extrapolation. It became clear that the pediatric development of secukinumab could be substantially accelerated by these novel ideas. Here, we report how these concepts were implemented in the pediatric development program of secukinumab in psoriasis, using a wide range of innovative quantitative techniques. This strategy led to the removal of the placebo arm from one trial, a substantial reduction of the overall sample size in this program, and a significantly faster approval of secukinumab for the pediatric psoriasis population.

Secukinumab in psoriasis: A single-center experience

Secukinumab in psoriasis: A single-center experience

Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey

Objectives The aim of this study was to examine the real-life efficacy and safety of secukinumab for psoriasis (PsO) along with the factors that could have an effect on clinical response. Methods Data in the charts of 121 patients with chronic PsO who were initiated secukinumab treatment between May-2018 and April-2020 with an observation period of up to 52 weeks were retrospectively analyzed. Demographic and clinical characteristics of patients, Psoriasis Area and Severity Index (PASI) scores and side effects were evaluated. Results A 75%, 90%, and 100% reduction in the baseline PASI score was observed in 84.3%, 68.6%, and 18.2% of patients at week 16, respectively. Obesity and previous biologic experience were important predictive factors for PASI 75 response at week 16. CRP levels, previous biological experience and age at PsO onset are found to be important factors in defining the need for updosing. Side-effect rates (9.7%) were not higher among patients with concomitant medications (13.6%) and dose escalation (13.3%). Conclusion Our results are in line with the efficacy and safety profiles of secukinumab in PsO reported previously. Dose escalation and the addition of concomitant medications may increase response rates.

LB1142 Characterization of the response to secukinumab in psoriasis using novel immunologic and genetic profiling

LB1142 Characterization of the response to secukinumab in psoriasis using novel immunologic and genetic profiling

Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance.

There are limited data regarding the long-term continuation with biological therapy for patients with psoriasis. In particular, the reasons for secukinumab discontinuation have not been thoroughly investigated. To better ascertain the real-life continuation of secukinumab in psoriasis, we conducted a retrospective study to evaluate the incidence, causes and factors of secukinumab discontinuation in patients with psoriasis. All patients treated with secukinumab for psoriasis in the Department of Dermatology (Toulouse University and Larrey Hospital, Toulouse, France), between September 2011 and June 2017, were enrolled in the study. Of the 91 patients in the study, 22 (24.2%) discontinued secukinumab. In 14 (15%) patients, the discontinuation was due to loss of efficacy. Two patients stopped treatment because they planned a pregnancy and five patients stopped because of adverse events. A longer disease duration (P=0.01) and presence of palmoplantar psoriasis (P=0.01) seem to be predictive factors for treatment failure. Patients reaching 90 or 100% improvement in Psoriasis Area and Severity Index (PASI90 and PASI100, respectively) at weeks 12-16 had a lower risk of long-term treatment discontinuation compared with patients who had less complete clearance (P=0.04). Long-term persistence of secukinumab appears to be good, as only 24.2% (n=22) of the patients in this study discontinued secukinumab over the follow-up period. Loss of efficacy prompted discontinuation in about 14% of patients by the 2-year follow-up. Persistence appears to be lower in patients with palmoplantar psoriasis and in patients previously exposed to many systemic treatments. Optimal therapeutic response at 12-16weeks as defined by reaching PASI90-100 seems to be predictive of long-term treatment persistence.

Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy

Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy

029 JAK inhibitors prevent and reverse vitiligo in mice, but do not eliminate established autoreactive T cells in the skin

Vitiligo is an autoimmune disease in which autoreactive, cytotoxic CD8+ T cells destroy the pigment producing melanocytes, resulting in disfiguring, well-defined white patches on the skin. The IFN-gamma-induced chemokines CXCL9 and CXCL10, primarily produced by keratinocytes, are required to recruit autoreactive CD8+ T cells to the skin. Activation of the JAK/STAT pathway is required for efficient production of these chemokines and subsequent T cell recruitment. Targeting this critical pathway has been shown to work effectively for case studies. In this study, we aimed to reduce recruitment of the cytotoxic CD8+ T cells to the skin and prevent subsequent melanocyte death by inhibiting the JAK pathway with the small molecules inhibitors tofacitinib and ruxolitinib. We tested these JAK inhibitors in our mouse model of vitiligo as both prophylactic and therapeutic treatments. In prophylaxis experiments, these inhibitors lowered the clinical vitiligo scores, chemokine expression of CXCL10 within the epidermis and dermis, and reduced cytotoxic CD8+ T cell accumulation in skin compartments. In therapeutic treatments, mice with established vitiligo successfully repigmented their lesions. Surprisingly, repigmentation did not correspond to lower cytotoxic CD8+ T cells in the epidermal and dermal compartments. This finding echoes the use of secukinumab in psoriasis, where autoimmune signaling is disrupted but the resident memory T cells are not reduced and other recent case studies that also suggest that JAK inhibitors are not durable for vitiligo. These data further support the role of JAK inhibitors as a treatment in both the progression and maintenance of vitiligo, although they may not be a durable treatment.

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

ObjectivesHere, we present the reported incidence rates of inflammatory bowel disease (IBD) in patients receiving treatment with secukinumab for psoriasis (PsO), psoriatic arthritis (PsA) or ankylosing spondylitis (AS), in a...

Secukinumab in psoriasis

Secukinumab in psoriasis

Ixekizumab or secukinumab in psoriasis: what difference does it make?

Linked Article:Warren et al. Br J Dermatol 2018; 178:1064–1071.

Secukinumab for psoriasis in a patient with hepatitis B

The case reported describes a 48-year-old man with congenital hepatitis B receiving secukinumab for treatment of psoriasis. Some biologic therapies have been associated with an increased risk of reactivation of hepatitis B. In the case of this patient, secukinumab has successfully managed his psoriasis without evidence of hepatitis B virus reactivation.

Secukinumab for the treatment of psoriatic arthritis

ABSTRACTIntroduction: Secukinumab (Cosentyx) is an interleukin-17A (IL-17A) inhibitor administered subcutaneously. Through 2016, it had received approval in a number of countries, including the USA, Japan and in the EU for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS).Areas covered: This review addresses the mechanism of action, efficacy and safety of secukinumab observed in clinical studies of patients with PsA. Data from recent studies of secukinumab in psoriasis, PsA and AS are included.Expert commentary: Secukinumab appears to be effective in improving various aspects of PsA, including improvements in psoriatic skin, enthesitis and dactylitis, as well as inhibition of the radiographic progression of peripheral arthritis. Secukinumab was in general well tolerated; the most common adverse events were nasopharyngitis, headache, and upper respiratory tract infection.

Secukinumab in psoriasis: Early improvement in patient-reported symptom diary predicts clinical response

Secukinumab in psoriasis: Early improvement in patient-reported symptom diary predicts clinical response

Secukinumab in psoriasis: Relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials

Secukinumab in psoriasis: Relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials